Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS-1893, a cardiac myosin inhibitor, in healthy subjects.

In 30 seconds

This Phase I randomized controlled trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS-1893, a cardiac myosin inhibitor, in healthy subjects. The study found that HRS-1893 was well tolerated, with maximum plasma concentrations ranging from 343 to 1090 ng/ml and favorable changes in cardiac indicators.

Key findings

• HRS-1893 was well tolerated across the tested dose range.
• Maximum plasma concentration ranged from 343 to 1090 ng/ml after single dosing.
• AUC 0-t ranged from 1890 to 10,100 h·ng/ml, indicating significant drug exposure.
• Food intake had no obvious effect on the pharmacokinetics of HRS-1893.

Why it matters

Understanding the safety and pharmacokinetics of new cardiac therapies is crucial for clinicians, as it informs potential therapeutic applications and patient management strategies in cardiovascular care.